New study aims to predict cancer return in Low-Risk patients
NCT ID NCT04604613
First seen Jun 27, 2026 · Last updated Sep 17, 2026 · Updated 2 times
Summary
This study looks at whether molecular testing and lymph node mapping can help predict if low-risk endometrial cancer will return after surgery. About 518 patients with early-stage, low-grade cancer will be followed for two years. The goal is to improve follow-up care by identifying who is most at risk of recurrence.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
518 people
The number who actually took part.
- Started
-
Nov 2012
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients diagnosed with low risk endometrial cancer who are scheduled to have a hysterectomy
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Histologically confirmed low grade (grade 1-2) endometrioid type adenocarcinoma * Candidate for surgery * No evidence of deep invasion or peritoneal disease in patients that have undergone preoperative imaging * Patients may have had prior hormonal treatment for the treatment of early endometrial neoplasia. Patients may not have had prior radiation or chemotherapy for treatment of endometrial cancer * Patients must have a negative pregnancy if of childbearing potential Exclusion Criteria: * Histologically confirmed high grade endometrioid or non-endometrioid type endometrial cancer (including serous, clear cell, carcinosarcoma or any mixed tumor containing these cell types) * Medical co-morbidities making surgery unsafe, as determined by the primary treating physician * Evidence of deep myometrial invasion, cervical involvement or peritoneal disease on preoperative imaging * Prior treatment with radiation or chemotherapy for endometrial cancer * Any contraindication to lymph node mapping
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Figo grade 1 endometrial endometrioid adenocarcinoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a hormonal IUD replace surgery for some uterine cancers?
- Weight-loss shot plus IUD may help reverse womb cancer without surgery
- Remote strength training aims to boost endometrial cancer survivorship in rural areas
- New drug combo aims to outsmart Chemo-Resistant ovarian cancer
- New combo therapy shows promise for Tough-to-Treat endometrial cancer
- Do tiny cancer cells in lymph nodes matter? new study aims to find out